Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • FGFR2 (Fibroblast growth factor receptor 2)
|
PD-L1 expression • HER-2 negative
|
Tecentriq (atezolizumab) • albumin-bound paclitaxel • tinengotinib (TT-00420)